NCT05227534

Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)

A Prospective Multi-canceR Early-detection and interVENTional Study in Asymptomatic Individuals: PREVENT

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 12,500 (estimated)
• Sponsor: Guangzhou Burning Rock Dx Co., Ltd. · Industry
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Accepted

Summary

PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.

Detailed description

Participants will receive the OverC multi-cancer detection blood test along with standard-of-care screening, whose results will be returned to health care providers and participants. The diagnostic procedures will be guided firstly by the OverC multi-cancer detection blood test and then by the standard-of-care screening. The number, cancer types, and cancer clinical stage of cancer patients diagnosed via the OverC multi-cancer detection blood test will be recorded. The study will enroll approximately 12,500 participants as defined by eligibility criteria with an anticipated enrollment period of approximately 9 months at up to 30 clinical sites within China. Participants will be actively followed for approximately 5 years from the date of their enrollment.

Conditions

• Cancer
• Early Detection of Cancer
• Circulating Cell-free DNA

Interventions

Type	Name	Description
DEVICE	OverC multi-cancer detection blood test	Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results

Timeline

• Start date: 2022-06-01
• Primary completion: 2024-03-01
• Completion: 2028-12-31
• First posted: 2022-02-07
• Last updated: 2022-07-06

Locations

1 site across 1 country: China